The FDA has issued a Class II recall for Teva Pharmaceuticals USA, Inc.'s Metoprolol Succinate Extended-Release Tablets, 200 mg, nationwide. The reason for the recall is that the drug failed to meet dissolution specifications, indicating a potential issue with its efficacy or performance. This recall impacts Teva Pharmaceuticals and its distribution network.

Pharmaceutical manufacturers and distributors must ensure they have identified and quarantined affected product lots. Compliance officers should verify that all product distributed nationwide has been accounted for and removed from shelves. While specific compliance deadlines are not detailed, prompt action is expected to mitigate patient risk and comply with FDA recall procedures.